Anixa Biosciences Inc (ANIX): Total Assets
$16.08M
As of 2025-10-31
$15.07M
As of 2026-07-31
-19.1%
3-year compound annual growth
+11.2%
5-year compound annual growth
+5.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $16.08M | -25.5% | 2026-01-12, Balance as of period end |
| 2024-10-31 | $21.59M | -15.4% | 2026-01-12, Balance as of period end |
| 2023-10-31 | $25.52M | -16.1% | 2025-01-10, Balance as of period end |
| 2022-10-31 | $30.41M | -16.1% | 2024-01-16, Balance as of period end |
| 2021-10-31 | $36.26M | +283.6% | 2023-01-04, Balance as of period end |
| 2020-10-31 | $9.45M | +50.2% | 2022-01-04, Balance as of period end |
| 2019-10-31 | $6.29M | -2.4% | 2021-01-07, Balance as of period end |
| 2018-10-31 | $6.45M | -26.8% | 2020-01-09, Balance as of period end |
| 2017-10-31 | $8.81M | +56.6% | 2019-01-11, Balance as of period end |
| 2016-10-31 | $5.63M | -39.7% | 2018-01-09, Balance as of period end |
| 2015-10-31 | $9.34M | +3.1% | 2016-12-08, Balance as of period end |
| 2014-10-31 | $9.06M | +66.5% | 2015-12-23, Balance as of period end |
| 2013-10-31 | $5.44M | -3.9% | 2015-01-29, Balance as of period end |
| 2012-10-31 | $5.66M | -34.5% | 2014-01-17, Balance as of period end |
| 2011-10-31 | $8.65M | -13.9% | 2013-01-29, Balance as of period end |
| 2010-10-31 | $10.05M | n/a | 2012-01-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $16.08M | -25.5% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $15.93M | -33.6% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $15.92M | +2.7% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $16.52M | -48.6% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $15.45M | -22.1% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $16.93M | -59.2% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $17.01M | -24.5% |
| Cingulate Inc. (CING) | 2025-12-31 | $15.07M | +1.4% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $14.98M | -41.2% |
Compare ANIX, APRE, RVPH, ADTX side by side · Screen every company in Pharmaceutical Preparations ↗